News
Weight-loss, diabetes drugs like Ozempic under review for side-effect reports
A short news item from 2024: the FDA is looking into reports of hair loss and suicidal thoughts in people taking Ozempic, Wegovy and Mounjaro.
Tirzepatide
Mounjaro · Zepbound · LY3298176
A medicine that mimics two gut hormones, GIP and GLP-1, which affect appetite and blood sugar. Approved in the EU and US for type 2 diabetes and obesity. Approval covers only these medicines.
This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.
- Type
- Mimics appetite hormones
- Stage
- Approved medicine
- Safety
- Well known
- Risk of fakes
- Medium
- Checked
- Not yet
Doping. Not banned. In 2026 WADA is collecting data on its use in sport.
Safety. Large studies and a US drug label. The label carries its strongest warning, on rare thyroid tumours in rats, and lists severe stomach and bowel problems. This describes the pharmacy medicine. Sources: US drug label, study 1.
Risk of fakes. Vials sold without prescription "for research" have been described. So far content tests cover semaglutide, not this substance. Sources: study 1, study 2.
Is it legal
| Where | Status | Checked | |
|---|---|---|---|
| PL | Prescription only | The EU-wide approval of Mounjaro covers Poland. The European medicines database (EMA) shows no separate Polish product (9 October 2026). Source | Not yet |
| EU | Prescription only | Approved across the EU as Mounjaro. This covers that medicine only, not products sold outside pharmacies. Source | Not yet |
| US | Prescription only | Prescription medicine (Mounjaro). Source | Not yet |
How much research exists
Scientific papers per year 2015–2025
These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.
What studies show
- AFat loss
Effect in studies. Weight fell by 20.9% on average at the highest dose studied, and by 3.1% on placebo, after 72 weeks. In people with diabetes it fell 12.8% to 14.7%, and 3.2% on placebo. Weight came back after stopping. The maker paid for the studies, which tested the pharmacy medicine.
Reported side effects
What doctors, patients and companies reported to the US medicines agency (FDA), and single cases described in medical journals. A report says what happened to someone after taking the substance. It does not prove the substance caused it, and it does not say how often it happens. Reports do not change any grade.
Reports to the FDA (USA)
- Reports
- 181,458
- Of these, serious
- 33,345
| Most often reported | Reports |
|---|---|
| Nausea | 19,774 |
| Pain where the needle went in | 14,625 |
| Diarrhoea | 11,346 |
| Vomiting | 9,429 |
| Constipation | 7,635 |
| Tiredness | 5,726 |
| Redness where the needle went in | 5,626 |
| Bleeding where the needle went in | 5,540 |
Serious means the person went to hospital, their life was in danger, they were left with lasting harm, or they died. One report can list several side effects. Most of these reports come from medical treatment, often of people who are ill, not from use outside medicine.
Cases described in medical journals
- Tirzepatide-associated severe euvolemic hyponatremia with syndrome of inappropriate antidiuretic hormone secretion-compatible biochemical features.
- Euglycemic Diabetic Ketoacidosis Following Treatment with Tirzepatide and SGLT-2 Inhibitors: A Case Report and Literature Review.
- Tirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect.
- Case Report: Panic attacks after tirzepatide injection in two female patients with recurrent depressive disorder.
- Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series.
- Confluent and reticulated papillomatosis improvement with tirzepatide-associated weight loss: A case report.
FDA reports come from openFDA, cases from a PubMed search. The editors have not read these cases yet. Titles stay in the original language. As of 3 Nov 2026.
Videos on YouTube
Creator
Jeff Nippard's Peptide Video: Here's What I Think
A coach responds to the Nippard video. According to the chapters in the description, he covers GLP-1 medicines using a client as an example, then BPC-157 and TB-500, the risk of products without quality control, and why to be sceptical of the claims.
The description has ads
Creator
The Best & Worst Peptides (Ranked)
A short video in which the author rates popular peptides on a scale from S to F. His ratings are an opinion on whether something is worth taking. Our grades from A to E only say how strong the studies are. The comparison below is based on the video description.
Creator
Peptides Are Insane
A bodybuilder with a biochemistry degree goes through peptides for weight loss, injury healing and longevity: what works, what the risks are and where studies are missing. The description lists his sources, mostly large studies of semaglutide and tirzepatide.
The description has ads
Took it themselves
1 Year on GLP-1 (Tirzepatide/Mounjaro): 52 Things That Actually Happened
A nurse practitioner describes a year on prescribed tirzepatide: 55 lb lost and 52 things that surprised her. It is one person's account of taking the medicine legally.
One person, no comparison group, and nobody knows what was in the product.
The description has ads
Studies we have read
| Studies | Kind of study | Who was studied | People | Duration | Dose as studied | Who paid |
|---|---|---|---|---|---|---|
| Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. | Random groups | Adults with obesity, randomised withdrawal | 670 | 88 wk | 10 or 15 mg weekly | Manufacturer |
| Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. | Random groups | Adults with obesity and type 2 diabetes | – | 72 wk | 10 or 15 mg weekly | Manufacturer |
| Tirzepatide Once Weekly for the Treatment of Obesity. | Random groups | Adults with obesity, without diabetes | 2539 | 72 wk | 5, 10 or 15 mg weekly | Manufacturer |
More papers we found
We found these papers automatically in PubMed. The editors have not read them yet, and they do not affect any grade. Titles stay in the original language.
Short answers
- Does tirzepatide work?
- A medicine that mimics two gut hormones, GIP and GLP-1, which affect appetite and blood sugar. Approved in the EU and US for type 2 diabetes and obesity. Approval covers only these medicines. Fat loss: grade A, effect in studies. Weight fell by 20.9% on average at the highest dose studied, and by 3.1% on placebo, after 72 weeks. In people with diabetes it fell 12.8% to 14.7%, and 3.2% on placebo. Weight came back after stopping. The maker paid for the studies, which tested the pharmacy medicine.
- Is Tirzepatide legal?
- PL: Prescription only. The EU-wide approval of Mounjaro covers Poland. The European medicines database (EMA) shows no separate Polish product (9 October 2026). EU: Prescription only. Approved across the EU as Mounjaro. This covers that medicine only, not products sold outside pharmacies. US: Prescription only. Prescription medicine (Mounjaro).
- Is tirzepatide banned in sport?
- Allowed, being watched, WADA 2026. Not banned. In 2026 WADA is collecting data on its use in sport.
- Is Tirzepatide safe?
- Well known. Large studies and a US drug label. The label carries its strongest warning, on rare thyroid tumours in rats, and lists severe stomach and bowel problems. This describes the pharmacy medicine.
Compare with SemaglutideCompare with RetatrutidePlain text for machines